Patel Girishchandra B, Ponce Amalia, Zhou Hongyan, Chen Wangxue
Institute for Biological Sciences, National Research Council of Canada, Ottawa, Ontario, Canada.
J Liposome Res. 2008;18(2):127-43. doi: 10.1080/08982100802129232.
Intranasal administration of ovalbumin (OVA) formulated in an archaeal lipid mucosal vaccine adjuvant and delivery (AMVAD) system prepared by the addition of CaCl2 to small unilamellar archaeosomes (liposomes made from archaeal polar lipids) containing encapsulated OVA, was recently shown to elicit strong and sustained OVA-specific mucosal and systemic immune responses. In this study, we show that the centrifugation/washing and antigen quantization steps required in the standard protocol for obtaining OVA/AMVAD model vaccine formulations can be eliminated by using simpler protocols such as admixing OVA with preformed empty archaeosomes, or by changing the starting ratio (w/w) of archaeal lipid to antigen at the archaeosome preparation stage, prior to the addition of CaCl2 to convert to the AMVAD structures. Irrespective of the vaccine preparation protocol, the AMVAD particle typically comprised of larger spherical structures that had aggregated like a bunch of grapes, and it contained aqueous compartment(s). The anti-OVA IgA antibody responses in vaginal wash, nasal wash, serum, and bile samples, and the anti-OVA IgG antibody responses in sera, in mice intranasally immunized with the OVA/AMVAD formulations prepared by the simplified or the standard protocols, were comparable.
在含有包封卵清蛋白（OVA）的小单层古脂质体（由古极性脂质制成的脂质体）中添加氯化钙制备的古脂质粘膜疫苗佐剂与递送（AMVAD）系统中配制的OVA经鼻内给药，最近显示可引发强烈且持续的OVA特异性粘膜和全身免疫反应。在本研究中，我们表明，通过使用更简单的方案，如将OVA与预先形成的空古脂质体混合，或在制备古脂质体阶段、在添加氯化钙转化为AMVAD结构之前改变古脂质与抗原的起始比例（w/w），可以省去获得OVA/AMVAD模型疫苗制剂的标准方案中所需的离心/洗涤和抗原定量步骤。无论疫苗制备方案如何，AMVAD颗粒通常由聚集在一起像一串葡萄的较大球形结构组成，并且它含有水相区室。用简化或标准方案制备的OVA/AMVAD制剂经鼻内免疫的小鼠，其阴道冲洗液、鼻腔冲洗液、血清和胆汁样本中的抗OVA IgA抗体反应以及血清中的抗OVA IgG抗体反应相当。
